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Abstract
During immune-complex-mediated arthritis (ICA), severe 
cartilage destruction is mediated by Fcy receptors (FcyRs)
(mainly FcyRI), cytokines (e.g. IL-1), and enzymes (matrix 
metalloproteinases (MMPs)). IL-13, a T helper 2 (Th2) cytokine 
abundantly found in synovial fluid of patients with rheumatoid 
arthritis, has been shown to reduce joint inflammation and bone 
destruction during experimental arthritis. However, the effect on 
severe cartilage destruction has not been studied in detail. We 
have now investigated the role of IL-13 in chondrocyte death 
and MMP-mediated cartilage damage during ICA. IL-13 was 
locally overexpressed in knee joints after injection of an 
adenovirus encoding IL-13 (AxCAhIL-13), 1 day before the 
onset of arthritis; injection of AxCANI (an empty adenoviral 
construct) was used as a control. IL-13 significantly increased 
the amount of inflammatory cells in the synovial lining and the
Keywords: cartilage destruction, experimental arthritis, interleukin-13, Fcy receptors, MMPs
joint cavity, by 30% to 60% at day 3 after the onset of ICA. 
Despite the enhanced inflammatory response, chondrocyte 
death was diminished by two-thirds at days 3 and 7. The mRNA 
level of FcyRI, a receptor shown to be crucial in the induction of 
chondrocyte death, was significantly down-regulated in 
synovium. Furthermore, MMP-mediated cartilage damage, 
measured as neoepitope (VDIPEN) expression using 
immunolocalization, was halved. In contrast, mRNA levels of 
MMP-3, -9, -12, and -13 were significantly higher and IL-1 
protein, which induces production of latent MMPs, was 
increased fivefold by IL-13. This study demonstrates that IL-13 
overexpression during ICA diminished both chondrocyte death 
and MMP-mediated VDIPEN expression, even though joint 
inflammation was enhanced.
Open Access
Introduction
One of the main pathological features of rheumatoid arthri­
tis is marked destruction of cartilage [1]. This destruction 
starts with reversible proteoglycan depletion, which is fol­
lowed by irreversible cartilage degradation defined as 
chondrocyte death and breakdown of collagen type II, 
eventually leading to matrix erosion. The latter is mainly 
induced by matrix metalloproteinases (MMPs), which gen­
erate specific cleavage sites within matrix molecules [2,3].
MMPs are secreted in an inactive form by IL-1-stimulated 
chondrocytes, synovial macrophages, and fibroblasts [4-6]. 
Activation of MMPs is still poorly understood, but MMP 
activity is primarily found in experimental immune-complex 
(IC)-dependent arthritis models.
Immunoglobulin G (IgG)-containing ICs can activate mac­
rophages upon recognition by Fcy receptors (FcyRs). 
Three classes of murine FcyR can be distinguished: FcyRI,
AxCAhIL-13 =  adenovirus encoding interleukin-13; AxCANI =  adenovirus encoding no gene; Ct =  cycle threshold; FcyR =  Fcy receptor; IC =  immune 
complex; ICA =  immune-complex-mediated arthritis; IFNy =  interferon y; IgG =  immunoglobulin G; IL =  interleukin; KC =  mouse homologue for human 
IL-8; MMP =  matrix metalloproteinase; NADPH =  reduced nicotinamide adenine dinucleotide phosphate; PMN =  polymorphonuclear neutrophil; RT- 
PCR =  reverse transcriptase polymerase chain reaction; Th, T helper. R392
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II, and III. Triggering FcyRI and III activates cellular 
responses, whereas FcyRII is an inhibitory receptor [7]. 
Previous studies have showed that activating FcyRI and III 
are crucial in induction of severe cartilage destruction, 
since chondrocyte death and MMP-mediated cartilage 
damage were absent in FcyR-deficient mice after induction 
of immune-complex-mediated arthritis (ICA) [8]. Further­
more, cartilage damage is aggravated by local overexpres­
sion of the proinflammatory T helper (Th) 1 cytokine IFNy 
[9]. This increase in cartilage destruction was observed 
only in IC-dependent arthritis models [9]. FcyRI was found 
to be crucial in the induction of chondrocyte death, 
whereas both FcyRI and III mediated MMP-mediated 
expression of VDIPEN [9].
Since the Th 1 cytokine IFNy worsens the arthritic response 
by up-regulation of the activating FcyRs, overexpression of 
a Th2 cytokine during arthritis might be protective, because 
of down-regulation of these receptors. In earlier studies, we 
found that adenoviral overexpression of IL-4 resulted in 
reduced MMP-mediated cartilage damage and chondro­
cyte death during ICA and arthritis induced by collagen 
type II [10,11]. IL-4 is regarded as a potent anti-inflamma­
tory cytokine by direct inhibition of proinflammatory 
cytokines such as IFNy, IL-1, and tumor necrosis factor a 
[12]. However, IL-4 protein and mRNA are hardly detected 
in synovial fluid and synovium of rheumatoid arthritis 
patients [13]. In contrast, IL-13 is expressed in rheumatoid 
arthritis synovial fluid and synovial fluid macrophages and 
resembles many functions of IL-4 [14,15]. Systemic overex­
pression of IL-13 in collagen-type-II-induced arthritis and 
local overexpression of IL-13 in rat adjuvant-induced arthri­
tis reduced joint inflammation and bone destruction 
[16,17]. However, the effect of IL-13 on cartilage destruc­
tion was not investigated in detail in these studies and 
remains to be elucidated.
In the present study, we investigated whether IL-13 influ­
ences the development of chondrocyte death and MMP- 
mediated VDIPEN expression in ICA. Subsequently, regu­
lation of FcyR, MMP, and IL-1 expression by IL-13 was 
studied, as these are important mediators in severe carti­
lage damage.
The present study demonstrates that overexpression of IL- 
13 in arthritic knee joints reduces chondrocyte death and 
MMP-mediated VDIPEN expression despite enhanced joint 
inflammation. Injection of an adenovirus encoding for IL-13 
diminished chondrocyte death, which correlated with 
down-regulation of FcyRI expression in the synovium. 
Reduction of MMP-mediated VDIPEN expression was not 
reflected by MMP mRNA and IL-1 concentrations, as these 
were increased.
Materials and methods
Animals
C57BI/6 male mice (10 to 12 weeks old) were purchased 
from Elevage-Janvier (Le Genest Saint Isle, France). Mice 
were fed a standard diet and tap water ad libitum. Ethical 
approval was obtained from the research ethics committee 
of the Central Animal Facility in Nijmegen.
Local gene transfer of IL-13
The recombinant adenovirus encoding human IL-13 (AxC- 
AhIL-13) was generated as described before [17-19] and 
an empty adenoviral construct (AxCANI) was used as con­
trol virus. AxCAhIL-13 or AxCANI (1.107 plaque-forming 
units) was injected intra-articularly in naive knee joints. 
Patellae with adjacent synovium were dissected in a stand­
ardized manner [20] and synovial biopsies were taken with 
a biopsy punch (diameter of 3 mm). Total RNA was 
extracted in 1 ml TRIzol reagent and used for quantitative 
PCR as described below. AxCAhIL-13 or AxCANI was 
injected intra-articularly 1 day before the induction of 
arthritis.
Induction of immune-complex-mediated arthritis
Rabbit polyclonal antibodies directed against lysozyme 
were injected intravenously into mice. ICA was then pas­
sively induced by injecting 3 |ig lysozyme coupled to poly- 
L-lysine in 6 |il pyrogen-free saline into the knee joints.
Histology of arthritic knee joints
Total knee joints were dissected at days 3 and 7 after the 
onset of arthritis. Joints were decalcified, dehydrated, and 
embedded in paraffin. Tissue sections (7 |im) were stained 
with hematoxylin and eosin.
Histopathological changes were scored in two ways. 
Inflammation was graded on a scale from 0 (no inflamma­
tion) to 3 (severely inflamed joint) as influx of inflammatory 
cells in synovium and joint cavity. Chondrocyte death was 
scored as the amount of empty lacunae expressed as a per­
centage of the total number of cells within the cartilage 
layers.
Immunohistochemical detection of macrophages and 
polymorphonuclear neutrophils (PMNs)
Macrophages were detected using a specific antibody 
against F4/80, a murine macrophage membrane antigen 
[21]. PMNs were visualized using NIMPR14, a specific rat 
anti-mouse monoclonal antibody [22]. Primary antibodies 
were detected using rabbit anti-rat IgG and avidin-horse- 
radish peroxidase conjugate. Finally, sections were coun­
terstained with hematoxylin. Macrophage and PMN 
subsets were quantitatively measured using an image anal­
ysis system. The inflammatory cell mass was selected by 
hand and the amount of positive features present in this 
area was displayed using a computer imaging system.
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Table  1
P rim ers fo r  de tec tio n  o f m urine  FcyRI, II, and III mRNA
Gene Primer Primer sequence
GAPDH Up
Low
5'-GGC-AAA-TT C-AAC-GGC-ACA-3' 
5'-GTT-AGT-GGG-GTC-TCG-CTC-CTG-3'
FcyRI Up
Low
5'-ACA-CAA-TGG-TTT-ATC-AAC-GGA-ACA-3'
5'-TGG-CCT-CTG-GGA-TGC-TAT-AAC-T-3'
FcyRII Up
Low
5'-GAC-AGC-CGT-GCT-AAA-TCT-TGC-T-3'
5'-GTG-TCA-CCG-TGT-CTT-CCT-TGA-G-3'
FcyRIII Up
Low
5'-GAC-AGG-CAG-AGT-GCA-GCT-CTT-3'
5'-TGT-CTT-CCT-TGA-GCA-CCT-GGA-T-3'
MMP-3 Up
Low
5'-TGG-AGC-TGA-TGC-ATA-AGC-CC-3'
5'-TGA-AGC-CAC-CAA-CAT-CAG-GA-3'
MMP-9 Up
Low
5'-GGA-ACT-CAC-ACG-ACA-TCT-TCC-A-3'
5'-GAA-ACT-CAC-ACG-CCA-GAA-GAA-TTT-3'
MMP-12 Up
Low
5'-GGA-CAT-GAA-GCG-TGA-GGA-TGT-3'
5'-GAA-GTC-TCC-GTG-AGC-TCC-AAA-T-3'
MMP-13 Up
Low
5'-ACC-TTG-TGT-TTG-CAG-AGC-ACT-AAC-TT-3'
5'-CTT-CAG-GAT-TCC-CGC-AAG-AGT-3'
MMP-14 Up
Low
5'-AAG-GCT-GAT-TTG-GCA-ACC-AT-3'
5'-GTC-CCA-AAC-TTA-TCC-GGA-ACA-C-3'
Primer sequences used for RT-PCR on synovium. FcyR, Fcy receptor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MMP, matrix 
metalloproteinase.
Three sections of each knee joint were measured and the 
mean was calculated. We report the amount of positive fea­
tures per 100,000 |im2 inflammatory cell mass in the 
synovium.
Immunohistochemical VDIPEN staining
Sections were digested with proteinase-free chondroiti- 
nase ABC (0.25 units/ml in 0.1 M Tris/HCl, pH 8.0; Sigma, 
Zwijndrecht, The Netherlands) to remove the side chains of 
proteoglycans followed by incubation with affinity-purified 
rabbit anti-VDIPEN IgG [23]. The primary antibody was 
detected using biotinylated goat anti-rabbit IgG, and avi-
din-streptravidin-peroxidase (Elite kit; Vector, Burlingame,
CA, USA). Counterstaining was done with orange G (2%).
Areas of immunostaining were expressed as a percentage 
of the total cartilage surface.
Quantitative detection of FcyR and MMP mRNA using 
RT-PCR
Specific mRNA levels for FcyRI, II, and III and MMP-3, -9, -
12, -13, and -14 were detected using the ABI/PRISM 7000 
Sequence Detection System (ABI/PE; Foster City, CA,
USA). Briefly, 1 |ig of synovial RNA was used for RT-PCR. 
mRNA was reverse transcribed to cDNA using oligodT
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F igure  1
Adenoviral-vector-mediated IL-13 expression in knee joints of C57Bl/6 mice. (a) Naive knee joints and (b) total knee joint sections 24 hours after 
injection of AxCANI (adenovirus encoding no gene) or of (c) AxCAhIL-13 (adenovirus encoding interleukin-13). Injection of AxCAhIL-13 resulted in 
0.4 ng/ml IL-13 at day 1, which increased to 5.5 ng/ml by day 7 (a). Injection of AxCANI resulted in a mild thickening of the synovial lining (S) and 
some invading inflammatory cells in the joint cavity (JC) (b), whereas no inflammation was observed after AxCAhIL-13 injection (c). Plotted values are 
means ±  SEM of data from 5 mice. *P <  0.05. Original magnification 200x. F, femur; P, patella.
primers. cDNA (1/100) was used in one PCR amplification. 
PCR was performed in SYBR Green Master Mix using the 
following amplification protocol: 2 min at 50°C followed by 
40 cycles of 15 s at 95°C and 1 min at 60°C with data col­
lection in the last 30 s. Message for murine FcyRI, II, and III 
and MMP-3, -9, -12, -13, and -14 was amplified using the 
primers listed in Table 1 (Biolegio, Malden, The Nether­
lands) at a final concentration of 300 nmol/l. Relative quan­
tification of the PCR signals was performed by comparing 
the cycle threshold value (Ct) of the FcyR and MMP genes 
in the different samples after correction of the GAPDH con­
tent for each individual sample.
Determination of cytokine and chemokine 
concentrations
To determine concentrations of IL-13, IL-1 p, KC (a mouse 
homologue for human growth-related protein), and macro­
phage inflammatory protein 1a in patella washouts, syno­
vial specimens were isolated in a standard manner [20] and 
incubated in 200 |il RPMI 1640 medium (GIBCO BRL, 
Breda, The Netherlands) for 1 hour at room temperature. 
Cytokine and chemokine concentrations were determined
R395
using the BioPlex® system from BioRad (Hercules, CA, 
USA) for the Luminex® multi-analyte system and expressed 
as pg/ml.
Statistical analysis
Differences between experimental groups were tested for 
significance using the Mann-Whitney U test. P  values 
<0.05 were considered statistically significant.
Results
Local IL-13 expression in naive knee joints using 
adenoviral gene transfer
The expression of IL-13 was determined in synovial wash­
outs at days 1, 2, 3, and 7 after injection of the AxCAhIL-13 
virus. IL-13 reached a concentration of 0.4 ng/ml after 24 
hours. Values increased to 2 ng/ml at day 2 and remained 
high up to 7 days after injection (Fig. 1a). IL-13 was not 
detected after injection of AxCANI.
We next investigated whether injection of the adenoviral IL- 
13 construct causes joint inflammation by itself. Using his­
tology, we found that IL-13 overexpression in naive knee
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joints did not recruit inflammatory cells at day 1, 2, 3, or 7 
(Fig. 1c). Injection of AxCANI resulted in minor cell influx in 
the synovial lining and joint cavity (Fig. 1b), which was not 
detectable from day 2 onwards.
IL-13 overexpression during ICA enhances joint 
inflammation and alters the composition of the cell mass
To investigate whether IL-13 overexpression ameliorated 
the arthritic response, we injected AxCAhIL-13 1 day 
before ICA induction. Joint inflammation was studied 3 and 
7 days after arthritis onset.
IL-13 overexpression significantly increased the inflamma­
tory cell mass in joint cavity and synovium, by 60% and 
30%, respectively, 3 days after arthritis induction (Fig. 2a). 
After 7 days, joint inflammation seemed to normalize in the 
IL-13 group (Fig. 2b).
To further investigate inflammatory cell types attracted by 
IL-13, PMNs and macrophages were detected using spe­
cific NIMPR14 and F4/80 antibodies respectively using 
immunolocalization.
At day 3, the amount of PMNs and macrophages was not 
markedly altered by IL-13 (Fig. 3a and 3 B). At day 7, how­
ever, the amount of PMNs in the synovial lining was 10 
times higher (Fig. 3a), whereas the amount of macrophages 
in the IL-13 group was half that in the mice without IL-13 
(Fig. 3b).
KC concentration in synovial washouts is augmented by 
IL-13
A possible mechanism by which IL-13 can increase joint 
inflammation in the presence of ICs is elevation of chemok- 
ine production. To investigate this, synovial washouts were 
done on days 3 and 7, and the chemokines KC (chemotac- 
tic for neutrophils) and macrophage inflammatory 
protein1a (chemotactic for macrophages) were measured. 
Local IL-13 overexpression increased KC concentrations 
4- and 18-fold, respectively, at days 3 and 7 after arthritis 
induction, which correlates with the high amount of PMNs 
(Table 2). Macrophage inflammatory protein1a 
concentrations at day 3 were comparable between the 
control and IL-13 groups. At day 7, macrophage inflamma­
tory protein1a expression was slightly increased by IL-13 
(Table 2).
IL-13 strongly inhibits chondrocyte death during ICA: 
down-regulation of FcyRI
Because IL-13 enhanced the inflammatory response, we 
next investigated the effect of IL-13 overexpression on car­
tilage destruction. A characteristic feature of irreversible 
cartilage damage is chondrocyte death; this was scored as 
the percentage of empty lacunae relative to the total
F igure  2
Jointinflammationinarthritic knee joints of C57Bl/6 m iceinjectedw ith 
AxCANI (adenovirus encoding no gene) or AxCAhIL-13 (adenovirus 
encoding interleukin-13). At (a) day 3 and (b) day 7 after the onset of 
immune-complex-mediated arthritis. The inflammatory cell mass was 
significantly enhanced by IL-13 in both the joint cavity and the synovium 
3 days after arthritis induction. Bars show the means ±  SEM for 10 
mice. Significance was evaluated using the Mann-Whitney U test. *P <  
0.05.
amount of chondrocytes present in various cartilage layers 
in the knee joint.
Three days after ICA induction, chondrocyte death, 
expressed as the mean for six cartilage layers in the knee 
joint, was very low in the IL-13 group (5%) and significantly 
less than in the control arthritic knee joints, which showed 
25% chondrocyte death (Fig. 4a). At day 7, chondrocyte 
death was even more significantly reduced (65%) in com­
parison with the control group (Fig. 4a).
In a previous study, we found that FcyRI is the dominant 
receptor mediating chondrocyte death during ICA [9]. We 
speculated that the decreased chondrocyte death might be 
caused by down-regulation of FcyRI by IL-13. For that rea-
R396
A rthritis  Research & Therapy Vol 7 No 2 Nabbe et al.
F igure  3
Immunohistochemicaldetection of inflammatory cells in knee joints of 
mice with immune-complex-mediated arthritis (ICA). (a) Polymorphonu­
clear neutrophils and (b) macrophages in synovium 3 and 7 days after 
injection of AxCANI (adenovirus encoding no gene) or AxCAhIL-13 
(adenovirus encoding interleukin-13). Polymorphonuclear neutrophils 
were detected using the specific rat anti-mouse monoclonal antibody 
NIMPR14, and macrophages were detected using an antibody against 
the membrane marker F4/80. At day 7, the amount of NIMPR1 4-posi­
tive features was significantly higher in the synovium of AxCAhIL-13- 
injected arthritic knee joints, while the amount of F4/80-positive fea­
tures was significantly lower. The bars represent means ±  SEM for 10 
mice. Data were evaluated using the Mann-Whitney U test. *P <  0.05.
son, we determined the effect of IL-13 on mRNA levels of 
all three classes of FcyRs in synovium. Cycle values of 
FcyRI, II, and III in synovium of arthritic knee joints injected 
with AxCANI were subtracted from cycle values of FcyRs 
after AxCAhIL-13 injection. Interestingly, FcyRI mRNA level 
was decreased by IL-13 at day 3 after ICA induction (ACt 
=  2), and was still slightly down-regulated at day 7 (ACt =
0.5). In contrast, FcyRII and FcyRIII were up-regulated by 
IL-13, at both days 3 and 7 after ICA induction (Fig. 4 b).
IL-13 increases IL-1 production and MMP mRNA levels in 
the arthritic knee joint
Cartilage matrix degradation is largely mediated by MMPs. 
Production of latent MMPs is mainly regulated by IL-1 and
this cytokine has been shown to be crucial in the genera­
tion of MMP-mediated neoepitopes [23]. The production of 
IL-1 was determined in synovial washouts of arthritic knee 
joints at both days 3 and 7. At day 3, IL-1 concentration 
was between 450 and 500 pg/ml in both the control and 
the IL-13 group. However, at day 7, the IL-1 concentration 
was reduced in the control group but remained high in the 
IL-13 group (control 54 pg/ml vs IL-13 255 pg/ml).
This sustained IL-1 production at day 7 may result in high 
concentrations of MMPs in synovium. Levels of MMP-3, -9, 
-12, -13, and -14 mRNA were detected by quantitative 
PCR. MMP-12 mRNA levels were increased 10-fold and 8 ­
fold by IL-13 at days 3 and 7, respectively, after the onset 
of ICA. At day 7, mRNA levels of MMP-3, -9, and -13 were 
also significantly increased in the IL-13 group (Table 3).
MMP-mediated VDIPEN expression is reduced by IL-13 
overexpression
Increased IL-1 and MMP concentrations may induce 
enhanced MMP-mediated proteoglycan degradation and 
this was further investigated by detection of VDIPEN 
neoepitope expression in the cartilage.
In the control group, 35% of the cartilage surface 
expressed VDIPEN neoepitopes after 3 days (Fig. 5). Injec­
tion with AxCAhIL13 reduced VDIPEN expression by 43%, 
as only 20% VDIPEN expression was found in the IL-13 
group. The inhibitory effect of IL-13 was still present at day 
7 after arthritis induction, as only 10% VDIPEN expression 
was found in the IL-13 group compared to 25% in the con­
trol group (Fig. 5).
Discussion
In the present study, we have shown that local gene trans­
fer of IL-13 reduced severe cartilage destruction defined as 
chondrocyte death and MMP-mediated aggrecan damage 
during ICA.
Local IL-13 overexpression during IC-dependent arthritis 
enhanced joint inflammation. To exclude the possibility that 
IL-13 itself induces influx of inflammatory cells, as is found 
when IL-13 is overexpressed in the lung [24,25], AxCAhIL- 
13 was injected in naive knee joints. We observed that IL- 
13 overexpression in the knee joint did not recruit inflamma­
tory cells. This observation indicates that overexpression of 
IL-13 induces elevated joint inflammation in combination 
with IC triggering. In our IC-dependent arthritis model, we 
showed that joint inflammation is determined by activating 
FcyRIII [26]. In the present study, we find that IL-13 
increased expression of FcyRIII within the synovium, which 
is not in line with the study showing that IL-13 decreases 
FcyRIII expression on human monocytes [27].
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Table  2
E ffect o f IL-13 on chem ok ine  concen tra tions  (p g /m l)  in  a rth r it ic  jo in ts  in m ice
Group KC MIP1 a
ICA, day 3
AxCANI 56 ±  B 303 ±  6.B
AxCAhIL-13 196 ±  31* 344 ±  96
ICA, day 7
AxCANI 10 ±  6 157 ±  25
AxCAhIL-13 1 B4 ±  26* 26B ±  9B
Concentrations of KC and MIP1a were detected in synovial washouts of arthritic knee joints 3 and 7 days after arthritis induction. KC 
concentrations were significantly higher in arthritic knee joints injected with AxCAhIL-13 both at day 3 and 7. *P <  0.05 in comparison with 
AxCANI. AxCAhIL-13, adenovirus encoding interleukin-13; AxCANI, adenovirus encoding no gene; ICA, immune-complex-mediated arthritis; KC, 
mouse homologue for human IL-8; MIP 1a, macrophage inflammatory protein 1a.
Tab le  3
E ffect o f IL-13 on M M P  mRNA leve ls in  synovium  o f m ice w ith  ICA
ICA day 3 ICA day 7
AxCANI AxCAhIL-13 AxCANI AxCAhIL-13
MMP-3 5.7 ±  0.3 7.1 ±  0.B 4.2 ±  0.5 6.1 ±  0.2*
MMP-9 5.1 ±  0.2 4.B ±  0.3 0.2 ±  0.6 3.9 ±  0.5*
MMP-12 0.6 ±  0.4 5.B ±  1.1* 0.9 ±  1 B.1 ±  0.9*
MMP-13 3.2 ±  0.2 2.7 ±  0.3 4.3 ±  0.3 6.4 ±  0.3*
MMP-14 3.7 ±  0.4 4.9 ±  0.B 3.7 ±  1 3.7 ±  0.6
Expression profile of MMP-3, -9, -1 2, -13, and -14 mRNA levels after injection of AxCANI or AxCAhIL-13 in synovial biopsies isolated at day 3 and 
day 7 after arthritis onset. The Ct values for MMP genes in naive knee joints were subtracted from the Ct values for MMPs at day 3 and 7 after 
arthritis onset. Ct values were corrected for GAPDH content for each individual sample. Note that MMP-3, -9, -12, and -13 mRNA levels were 
significantly increased at day 7 by IL-13, and the MMP-12 mRNA level was already elevated at day 3. Values represent means ±  SEM for 5 mice. 
*P <  0.05, Mann-Whitney U test. AxCAhIL-13 =  adenovirus encoding interleukin-13; AxCANI =  adenovirus encoding no gene; Ct =  cycle 
threshold; GAPDH =  glyceraldehyde-3-phosphate dehydrogenase; ICA =  immune-complex-mediated arthritis; MMP =  matrix metalloproteinase.
However, regulation of FcyR expression on mouse macro­
phages by IL-13 has not been described. IL-13 has high 
similarity with IL-4, which can increase FcyRIII expression 
on murine mast cells [28]. Binding of IC to FcyRIII on mac­
rophage lining cells leads to activation, resulting in elevated 
influx of inflammatory cells. We further found that overex­
pression of IL-13 in arthritic knee joints particularly 
increased the amount of PMNs. This is in line with earlier 
studies in which it was shown that stimulation of FcyRIII 
induces release of PMN attracting chemokines as IL-8, 
resulting in neutrophil accumulation [29-31].
The proinflammatory action of IL-13 found in the present 
study seems to be dependent on costimulation with ICs to 
trigger arthritis onset, since local overexpression of IL-13 
during T-cell-mediated rat adjuvant-induced arthritis dimin­
ishes joint inflammation [17]. In the latter model, ICs do not 
play a role. Whether IL-13 decreases or enhances joint 
inflammation may also be dependent on systemic or local 
overexpression. Systemic overexpression of IL-13 during 
collagen-type-II-induced arthritis, in which FcyRIII is also
required for arthritis development [32], decreased joint 
inflammation [16]. An explanation may be that systemic 
overexpression of IL-13 hampers the development of the 
immune response by induction of isotype switching to the 
nonarthritogenic IgG4 and IgE [33,34], thereby ameliorat­
ing the arthritic response. Induction of immunity is hardly 
affected by local overexpression, as was shown when injec­
tion of AdIL-4 (adenovirus expressing IL-4) in knee joints 
during arthritis induced by collagen type II markedly 
increased the amount of inflammatory cells [11].
Cartilage destruction during ICA is mostly related to joint 
inflammation. Despite the enhanced influx of inflammatory 
cells, however, a significant reduction of chondrocyte death 
was induced by IL-13. Chondrocyte death may be the 
result of increased production of oxygen radicals, as reac­
tive oxygen species can mediate apoptosis [35]. In a previ­
ous study, we showed that there is a prominent role for 
FcyRI mediating chondrocyte death during ICA. In FcyRI- 
deficient mice, chondrocyte death was almost absent. 
When the Th1 cytokine IFNy was overexpressed, a signifi-
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F igure  4 F igure  5
Chondrocyte dea th in the  knee joints of mice with immune-complex- 
mediated arthritis (ICA). (a) At day 3 and 7 in arthritic knee joints 
injected with injected with AxCANI (adenovirus encoding no gene) or 
AxCAhIL-13 (adenovirus encoding interleukin-13) and (b) expression 
profiles of Fcy receptor I (FcyRI), II, and III mRNA levels induced by IL- 
13 in synovium. IL-13 significantly decreased chondrocyte death, both 
at day 3 and at day 7 (a). Cycle threshold (Ct) values of FcyRI, II, and III 
in arthritic knee joints injected with AxCANI were subtracted from the 
Ct values for FcyRs after injection of AxCAhIL-13. Ct values were cor­
rected for glyceraldehyde-3-phosphate dehydrogenase content for 
each individual sample. (b) FcyRI mRNA level was down-regulated by 
IL-13, whereas an up-regulation was observed for both FcyRII and III. 
Bars represent means ±  SEM for 10 mice. Mann-Whitney U test. *P <  
0.05. D, A.
cant increase in chondrocyte death was observed, which 
was dependent on FcyRI [9]. Stimulation of FcyRI leads to 
production of oxygen radicals via NADPH-oxidase [36]. In 
the present study, we find that in knee joints injected with 
AxCAhIL-13, FcyRI expression remained low, whereas in 
knee joints injected with control virus, FcyRI expression 
level was enhanced in the synovium. The decrease in 
chondrocyte death might be due to a reduced FcyRI con­
centration. Moreover, it has been shown that IL-13 itself 
down-regulates production of oxygen radicals by inflamma­
tory cells, since IL-13 can inhibit protein-kinase-C-triggered 
respiratory burst in monocytes [37]. The inhibiting effect of 
IL-13 on oxygen radical production seemed to be mono­
cyte-dependent, as no reduction was found in PMNs [38].
Matrix-metalloproteinase-mediated aggrecan damage in knee joints of 
mice with immune-complex-mediated arthritis. VDIPEN expression at 
day 3 and 7 after the induction of immune-complex-mediated arthritis in 
knee joints injected with AxCANI or AxCAhIL-13. Note that VDIPEN 
expression was reduced by IL-13 both at day 3 and day 7. Values rep­
resent the mean ±  SEM for 10 mice. *P <  0.05, Mann-Whitney U test. 
AxCAhIL-13 =  adenovirus encoding interleukin-13; AxCANI =  adenovi­
rus encoding no gene.
In addition, IL-13 also reduced MMP-mediated VDIPEN 
neoepitope expression. It has been reported that IL-13 
diminishes the breakdown of collagen and proteoglycans 
from bovine cartilage, by regulation of MMP expression 
[39]. Several mechanisms may inhibit MMP-mediated carti­
lage destruction, as regulation of MMPs occurs at three dif­
ferent levels: MMP synthesis, activation of latent enzyme, 
and MMP inhibition. IL-1 is a prominent cytokine controlling 
the production of latent MMPs [40], and diminished pro­
duction of IL-1 might reduce MMP-mediated cartilage dam­
age. We found, however, that IL-13 overexpression in 
arthritic knee joints strongly increased IL-1 p concentra­
tions. IL-13 is described as an anti-inflammatory cytokine, 
which in general reduces IL-1 p production [14,27,41]. 
However, the effect of IL-13 on IL-1 production by IC-stim- 
ulated macrophages has not been described to date. In 
addition to macrophages, fibroblasts and PMNs are also 
present in the knee joint at day 7 after the onset of arthritis.
The sustained production of IL-1 by IL-13 may indeed stim­
ulate MMP production, as reflected by enhanced MMP-3, - 
9, -12, and -13 mRNA levels 7 days after ICA induction in 
AxCAhIL-13-injected arthritic knee joints. MMP-12 mRNA 
level was already increased at day 3 after the onset of 
arthritis. It has been shown that MMP-12 expression is IL- 
13-dependent and that MMP-12 is a critical downstream 
mediator and regulator of IL-13-induced responses 
[42,43]. Furthermore, IL-13 induction of MMP-2, -9, and - 
13 is at least partly mediated by MMP-12 [43], indicating 
that MMP-12 may be a crucial enzyme inducing MMP- 
mediated cartilage damage.
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Furthermore, IL-13 might interfere at the level of activation 
of MMPs. MMPs are secreted in a latent form and activation 
occurs after cleavage of a propeptide. Factors that activate 
latent MMPs are still unknown. However, MMP-mediated 
VDIPEN expression is mainly found in IC-dependent arthri­
tis models, in which FcyRs are of utmost importance. 
Down-regulation of the activating FcyRs might reduce 
VDIPEN expression. Indeed, we found that IL-13 strongly 
diminished FcyRI expression in synovium. Another mecha­
nism involved in activation of MMPs is production of oxygen 
radicals. As mentioned above, stimulation of FcyRI results 
in assembly of the NADPH-oxidase complex, which pro­
duces oxygen radicals [36]. Additionally, oxygen metabo­
lites can be converted into H2O 2, which can activate latent 
proMMPs [44,45]. Taken together, decreased FcyRI 
expression reduces the production of oxygen radicals, 
which apart from chondrocyte protection may also result in 
diminished MMP-mediated VDIPEN expression.
Conclusion
The present study shows that IL-13 is a potent cytokine 
that protects the cartilage matrix against degradation dur­
ing ICA. In addition, these results indicate that regulation of 
the expression of FcyR, particularly FcyRI, might be 
involved in this process. Therefore, modulation of FcyRI by 
Th2 cytokines seems to be a promising therapeutic tool 
diminishing cartilage damage in rheumatoid arthritis.
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